Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Delayed elimination of SN-38 in cancer patients with severe renal failure.

Drug metabolism and disposition: the biological fate of chemicals - 1 Feb 2011

Fujita Ken-ichi, Sunakawa Yu, Miwa Keisuke, Akiyama Yuko, Sugiyama Minako, Kawara Kaori, Ishida Hiroo, Yamashita Keishi, Mizuno Keiko, Saji Shigehira, Ichikawa Wataru, Yamamoto Wataru, Nagashima Fumio, Miya Toshimichi, Narabayashi Masaru, Ando Yuichi, Hirose Takashi, Sasaki Yasutsuna

Abstract excerpt

This prospective study is designed to examine the effects of severe renal failure on the pharmacokinetics of irinotecan. The pharmacokinetics of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), and SN-38 glucuronide (SN-38G) in three cancer patients with severe renal failure [creatinine cleara...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronides

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Metabolic Clearance Rate

Share to Renal Dialysis

Share to Renal Insufficiency

Source

Identifiers

PMID: 20980446
DOI: 10.1124/dmd.110.035451

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20980446-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Delayed elimination of SN-38 in cancer patients with severe renal failure.PMID 20980446Read ↗

Concurrence of UGT1A polymorphism and end-stage renal disease leads to severe toxicities of irinotecan in a patient with metastatic colon cancer.Semantic proximity Read ↗

Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.Semantic proximity Read ↗

Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.Semantic proximity Read ↗

Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients.Semantic proximity Read ↗

Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.Semantic proximity Read ↗

Life-threatening toxicities in a patient with UGT1A1*6/*28 and SLCO1B1*15/*15 genotypes after irinotecan-based chemotherapy.Semantic proximity Read ↗

Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.Semantic proximity Read ↗

Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.Semantic proximity Read ↗

P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.Semantic proximity Read ↗

Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele.Semantic proximity Read ↗

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.